Matches in SemOpenAlex for { <https://semopenalex.org/work/W2482548894> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- W2482548894 endingPage "53" @default.
- W2482548894 startingPage "47" @default.
- W2482548894 abstract "Chronotherapy for rheumatoid arthritis: current perspectives Hideto To Department of Medical Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan Abstract: Rheumatoid arthritis (RA) is an autoimmune disorder of unknown etiology. Morning stiffness, a characteristic feature of RA, shows a 24-hour rhythm. Cytokines, which are considered to play an important role in the pathogenesis of RA, also exhibit a 24-hour rhythm, with a peak in the early morning. These rhythms have been attributed to the endogenous hormone balance and changes in expression levels of clock-related genes. Chronotherapy based on the 24-hour rhythm of RA has been performed using glucocorticoids and disease-modifying antirheumatic drugs. In a previous study, it was reported that modified-release prednisone tablets were administered to patients with RA at night, which demonstrated that the severity of morning stiffness was markedly less than that in patients receiving the standard treatment. Methotrexate (MTX) is the most frequently used RA drug worldwide. In a basic study, cytokines and inflammatory responses in RA model animals showed 24-hour rhythms, based on which MTX was administered and exerted dosing time-dependent antirheumatic effects. Plasma C-reactive protein and cytokine levels also exhibit 24-hour rhythms in patients with RA, with peaks occurring in the early morning. MTX has been shown to markedly inhibit the exacerbation of arthritis in patients with RA when it is administered as inflammatory responses and tumor necrosis factor-α levels begin to increase. Tacrolimus (TAC) is an immunosuppressive agent that is administered to patients who undergo organ transplants. Since one of the mechanisms of action of TAC is the inhibition of inflammatory cytokine production, it is used as an RA therapeutic drug. When TAC was previously administered in the early light or early dark phase to RA model animals, the group treated in the early light phase had notably inhibited increase in arthritis scores compared with that in the early dark phase. The selection of an optimal dosing time associated with 24-hour rhythms in RA symptoms may lead to more effective and safer treatments for RA using glucocorticoids and disease-modifying antirheumatic drugs. Keywords: methotrexate, steroid, circadian rhythm, cytokines" @default.
- W2482548894 created "2016-08-23" @default.
- W2482548894 creator A5070620529 @default.
- W2482548894 date "2016-08-01" @default.
- W2482548894 modified "2023-10-11" @default.
- W2482548894 title "Chronotherapy for rheumatoid arthritis: current perspectives" @default.
- W2482548894 doi "https://doi.org/10.2147/cpt.s87421" @default.
- W2482548894 hasPublicationYear "2016" @default.
- W2482548894 type Work @default.
- W2482548894 sameAs 2482548894 @default.
- W2482548894 citedByCount "4" @default.
- W2482548894 countsByYear W24825488942020 @default.
- W2482548894 countsByYear W24825488942021 @default.
- W2482548894 countsByYear W24825488942023 @default.
- W2482548894 crossrefType "journal-article" @default.
- W2482548894 hasAuthorship W2482548894A5070620529 @default.
- W2482548894 hasBestOaLocation W24825488941 @default.
- W2482548894 hasConcept C126322002 @default.
- W2482548894 hasConcept C19720800 @default.
- W2482548894 hasConcept C2777077863 @default.
- W2482548894 hasConcept C2777575956 @default.
- W2482548894 hasConcept C2779910239 @default.
- W2482548894 hasConcept C2781059491 @default.
- W2482548894 hasConcept C71924100 @default.
- W2482548894 hasConcept C98274493 @default.
- W2482548894 hasConceptScore W2482548894C126322002 @default.
- W2482548894 hasConceptScore W2482548894C19720800 @default.
- W2482548894 hasConceptScore W2482548894C2777077863 @default.
- W2482548894 hasConceptScore W2482548894C2777575956 @default.
- W2482548894 hasConceptScore W2482548894C2779910239 @default.
- W2482548894 hasConceptScore W2482548894C2781059491 @default.
- W2482548894 hasConceptScore W2482548894C71924100 @default.
- W2482548894 hasConceptScore W2482548894C98274493 @default.
- W2482548894 hasLocation W24825488941 @default.
- W2482548894 hasOpenAccess W2482548894 @default.
- W2482548894 hasPrimaryLocation W24825488941 @default.
- W2482548894 hasRelatedWork W2020756831 @default.
- W2482548894 hasRelatedWork W2022712498 @default.
- W2482548894 hasRelatedWork W2138243862 @default.
- W2482548894 hasRelatedWork W2227428044 @default.
- W2482548894 hasRelatedWork W2314544353 @default.
- W2482548894 hasRelatedWork W2366611537 @default.
- W2482548894 hasRelatedWork W2396165291 @default.
- W2482548894 hasRelatedWork W2411121127 @default.
- W2482548894 hasRelatedWork W3030711132 @default.
- W2482548894 hasRelatedWork W4283524728 @default.
- W2482548894 hasVolume "Volume 6" @default.
- W2482548894 isParatext "false" @default.
- W2482548894 isRetracted "false" @default.
- W2482548894 magId "2482548894" @default.
- W2482548894 workType "article" @default.